A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti- α4 Integrin Monoclonal Antibody.

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody. Curr Drug Metab. 2018 Apr 27;: Authors: Hao L, Fang-Hong S, Shi-Ying H, Shun-Guo Z, Min-Ling C Abstract Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion molecule 1, LPAM-1) integrins, is approved for the treatment of Multiple sclerosis (MS) and Crohn's disease (CD). NAT has been well tolerated in pivotal trials. Progressive multifocal leukoencephalopathy (PML) is an uncommon but serious complications resulting from NAT treatment. It is not confirmed that higher NAT concentration increases the risk of PML. NAT can pass placental barrier before delivery and into breast milk. As MS is a disease that affects young women most, a proper risk-benefit analysis of NAT therapy in lactating women are still needed. Genome sequence variations in drug target proteins, drug-metabolizing enzymes, and drug transporters may alter the pharmacokinetics (PK) and pharmacodynamics (PD) properties of drugs and cause variable drug responses in individual patients. Pharmacogenomics research of NAT in MS or CD therapies are currently yielding an abundance of potential SNPs and markers of various outcomes of drug response. Gln-152, Lys-201, and Lys-256 are the three importan...
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research